MABIMMUNE
Table of contents:
The "MABIMMUNE" trademark, serial number 77569756 , was filed on 15th of September 2008 with a mark drawing code of 4000 and its transaction date is 77569756. Since 19th of April 2012, the document can be found in the L60 law office in the publication and issue section. The employee responsible is GOLD, BARBARA A and the date it was published for opposition on 05/19/2009. The status of this trademark was checked last on 09/22/2009.
The "MABIMMUNE" trademark, serial number 85683762 , was filed on 22nd of July 2012 with a mark drawing code of 4000 and its transaction date is 85683762. Since 10th of February 2014, the document can be found in the L20 law office in the publication and issue section. The status of the trademark was checked last on 02/10/2014.
The corresponded responsible for this trademark is JANICE HOUSEY, located at SYMBUS LAW GROUP LLC, PO BOX 11085, MC LEAN, VA 22102-7985.The state or country where the trademark was organized is by Mabimmune Diagnostics Ag. The legal entity type behing it is a Other (Indicates Entity-Statement should appear)., located at Wagistrasse 13, Schlieren, zip 8952.
| GOODS AND/OR SERVICES | |
| International Class - 001 - Chemicals used in industry, science and photography, as well as in agriculture, horticulture and forestry; unprocessed artificial resins; unprocessed plastics; manures; fire extinguishing compositions; tempering and soldering preparations; chemical substances for preserving foodstuffs; tanning substances; adhesives used in industry. | |
|---|---|
| U.S. Class | 046 - Foods and Ingredients of Foods |
| Class Status | 6 - Active |
| Status Date | 07/27/2012 |
| Primary Code | 001 |
| International Class - 003 - Bleaching preparations and other substances for laundry use; cleaning, polishing, scouring and abrasive preparations; soaps; perfumery, essential oils, cosmetics, hair lotions; dentifrices. | |
| U.S. Class | 052 - Detergents and Soaps |
| Class Status | 6 - Active |
| Status Date | 05/16/2013 |
| Primary Code | 003 |
| International Class - 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. | |
| U.S. Class | 052 - Detergents and Soaps |
| Class Status | 6 - Active |
| Status Date | 07/27/2012 |
| Primary Code | 005 |
| International Class - 041 - Education; providing of training; entertainment; sporting and cultural activities. | |
| U.S. Class | 107 - Education and Entertainment |
| Class Status | 6 - Active |
| Status Date | 05/16/2013 |
| Primary Code | 041 |
| International Class - 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. | |
| U.S. Class | 101 - Advertising and Business |
| Class Status | 6 - Active |
| Status Date | 07/27/2012 |
| Primary Code | 042 |
| International Class - 044 - Medical services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services. | |
| U.S. Class | 101 - Advertising and Business |
| Class Status | 6 - Active |
| Status Date | 07/27/2012 |
| Primary Code | 044 |
| Goods codes | |
| CC0000 | Color is not claimed as a feature of the mark. |
| GS0011 | Chemicals, namely, chemical preparations for biological assays; industrial chemicals; chemical preparations for scientific purposes; chemical preparations for use in photography; biological materials, namely, biological tissue and cell cultures other than for medical or veterinary purposes, inoculants in the nature of biological microorganisms used for biomedical research; biological preparations, namely, biological tissue and cell cultures other than for medical or veterinary purposes, inoculants in the nature of biological microorganisms used for biomedical research; peptides for chemicals and foodstuff, namely, peptide substrates used in analyzing and detecting certain biomarkers for laboratory or research use; polypeptides, namely, peptide substrates used in analyzing and detecting certain biomarkers for laboratory or research use, protein antibodies, namely, monoclonal antibodies for in vitro or in-vivo scientific or research use, antibody reagents used for the detection of antigens in cell and tissue analysis for in vitro diagnostic use; diagnostic preparations for scientific use; Biological compounds, namely, epitopes in the nature of enzyme or mis-folded proteins for use in the pre-clinical research and development of pharmaceutical preparations such as antibodies or active peptides |
| GS0031 | Skin care preparations, namely, chemical peels for skin, anti-aging topical creams, anti-wrinkle topical creams, non-medicated lotions which are indicated specifically for reducing scar formation, topical ointments indicated for accelerating the healing process or alleviating the symptoms of burns, namely, non-medicated ointments for the prevention and treatment of sunburn, topical beauty products, namely, cosmetics |
| GS0051 | Pharmaceutical preparations for keloid scar formation, dermal burns, lymphomas, sarcomas, carcinomas, and leukemias, inflammatory disease, cardiovascular disease, atherosclerosis, rheumatoid arthritis, stroke or an acute coronary syndrome such as myocardial infarction heart attack, chronic liver disease, cerebral venous thrombosis, deep venous thrombosis or pulmonary embolism, arterial thrombosis, aneurysm, heart failure, ischemic heart diseases, angina pectoris, sudden cardiac death, hypertensive heart disease, non-coronary vessel disease, such as atherosclerosis, small vessel disease, vascular dementia, nephropathy, hypertriglyceridemia, hypercholesterolemia, hyperlipidemia, xanthomatosis, asthma, hypertension, emphysema, chronic pulmonary disease, cardiomyopathies and a cardiovascular condition associated with an interventional procedure such as restenosis following angioplasty, placement of a stent, synthetic or neutral extension grafts; pharmaceutical preparations for the treatment of metabolic diseases including diabetes mellitus; veterinary preparations for keloid scar formation, dermal burns, lymphomas, sarcomas, carcinomas, and leukemias, inflammatory disease, cardiovascular disease, atherosclerosis, rheumatoid arthritis, stroke or an acute coronary syndrome such as myocardial infarction heart attack, chronic liver disease, cerebral venous thrombosis, deep venous thrombosis or pulmonary embolism, arterial thrombosis, aneurysm, heart failure, ischemic heart diseases, angina pectoris, sudden cardiac death, hypertensive heart disease, non-coronary vessel disease, such as atherosclerosis, small vessel disease, vascular dementia, nephropathy, hypertriglyceridemia, hypercholesterolemia, hyperlipidemia, xanthomatosis, asthma, hypertension, emphysema, chronic pulmonary disease, cardiomyopathies and a cardiovascular condition associated with an interventional procedure such as restenosis following angioplasty, placement of a stent, synthetic or neutral extension grafts; veterinary preparations for metabolic diseases including diabetes mellitus; tumor suppressing agents; preparations for treating neurodegenerative diseases; immunogenics, namely, pharmaceutical preparations for inducing immune responses for the treatment of oncology indications including lymphomas, sarcomas, carcinomas, leukemias, bacterial infections, parasitic disease; vaccines; antibodies, namely, for treatment of anti-inflammatory, cardiovascular, oncological, and dermatological indications; active epitopes in the form of a pharmaceutical preparation which modulate the biological activity of drug targets in-vivo; synthetic peptides for pharmaceutical purposes for the treatment of keloid scar formation, dermal burns, lymphomas, sarcomas, carcinomas, and leukemias, inflammatory disease, cardiovascular disease, atherosclerosis, rheumatoid arthritis, stroke or an acute coronary syndrome such as myocardial infarction heart attack, chronic liver disease, cerebral venous thrombosis, deep venous thrombosis or pulmonary embolism, arterial thrombosis, aneurysm, heart failure, ischemic heart diseases, angina pectoris, sudden cardiac death, hypertensive heart disease, non-coronary vessel disease, such as atherosclerosis, small vessel disease, vascular dementia, nephropathy, hypertriglyceridemia, hypercholesterolemia, hyperlipidemia, xanthomatosis, asthma, hypertension, emphysema, chronic pulmonary disease, cardiomyopathies and a cardiovascular condition associated with an interventional procedure such as restenosis following angioplasty, placement of a stent, synthetic or neutral extension grafts; synthetic peptides for pharmaceutical purposes for the treatment of metabolic diseases including diabetes mellitus; sanitary preparations for medical purposes; biological preparations for medical purposes for the treatment of keloid scar formation, dermal burns, lymphomas, sarcomas, carcinomas, and leukemias, inflammatory disease, cardiovascular disease, atherosclerosis, rheumatoid arthritis, stroke or an acute coronary syndrome such as myocardial infarction heart attack, chronic liver disease, cerebral venous thrombosis, deep venous thrombosis or pulmonary embolism, arterial thrombosis, aneurysm, heart failure, ischemic heart diseases, angina pectoris, sudden cardiac death, hypertensive heart disease, non-coronary vessel disease, such as atherosclerosis, small vessel disease, vascular dementia, nephropathy, hypertriglyceridemia, hypercholesterolemia, hyperlipidemia, xanthomatosis, asthma, hypertension, emphysema, chronic pulmonary disease, cardiomyopathies and a cardiovascular condition associated with an interventional procedure such as restenosis following angioplasty, placement of a stent, synthetic or neutral extension grafts; biological preparations for medical purposes for the treatment of metabolic diseases including diabetes mellitus; biocides; diagnostic preparations for medical or veterinary purposes; sanitary towels; dietetic food, namely, pasta, crackers, bread adapted for medical purposes; dietetic beverages, namely, tea, vitamin fortified beverages, protein shakes adapted for medical purposes; algaecide chemicals for swimming pools; biological tissue such as bone, skin, blood vessels, cartilage, muscle, teeth, extracellular matrix, and heart valve tissue intended for subsequent implantation; synthetic peptides and polypeptides for the treatment of keloid scar formation, dermal burns, lymphomas, sarcomas, carcinomas, and leukemias, inflammatory disease, cardiovascular disease, atherosclerosis, rheumatoid arthritis, stroke or an acute coronary syndrome such as myocardial infarction heart attack, chronic liver disease, cerebral venous thrombosis, deep venous thrombosis or pulmonary embolism, arterial thrombosis, aneurysm, heart failure, ischemic heart diseases, angina pectoris, sudden cardiac death, hypertensive heart disease, non-coronary vessel disease, such as atherosclerosis, small vessel disease, vascular dementia, nephropathy, hypertriglyceridemia, hypercholesterolemia, hyperlipidemia, xanthomatosis, asthma, hypertension, emphysema, chronic pulmonary disease, cardiomyopathies and a cardiovascular condition associated with an interventional procedure such as restenosis following angioplasty, placement of a stent, synthetic or neutral extension grafts; synthetic peptides and polypeptides for the treatment of metabolic diseases including diabetes mellitus; chemicals, namely, chemical preparations for pharmaceutical or medical purposes, namely, for keloid scar formation, dermal burns, lymphomas, sarcomas, carcinomas, and leukemias, inflammatory disease, cardiovascular disease, atherosclerosis, rheumatoid arthritis, stroke or an acute coronary syndrome such as myocardial infarction heart attack, chronic liver disease, cerebral venous thrombosis, deep venous thrombosis or pulmonary embolism, arterial thrombosis, aneurysm, heart failure, ischemic heart diseases, angina pectoris, sudden cardiac death, hypertensive heart disease, non-coronary vessel disease, such as atherosclerosis, small vessel disease, vascular dementia, nephropathy, hypertriglyceridemia, hypercholesterolemia, hyperlipidemia, xanthomatosis, asthma, hypertension, emphysema, chronic pulmonary disease, cardiomyopathies and a cardiovascular condition associated with an interventional procedure such as restenosis following angioplasty, placement of a stent, synthetic or neutral extension grafts; pharmaceutical preparations, namely, medicated scar-reducing lotions; burn relief medication ointments; Chemicals, namely, chemical preparations for medical kits and tests, namely, diagnostic blood tests, companion diagnostics, and blood tests to determine the efficacy of the treatment strategy including both plasma and serum based assays for metabolic, cardiovascular, oncological, and inflammatory diseases |
| GS0411 | Physical examination, namely, physical fitness training services, physical performance monitoring in the nature of physical fitness consultation |
| GS0421 | Testing, inspection or research of pharmaceuticals, cosmetics or foodstuffs; consultancy and providing information of testing, inspection or research of pharmaceuticals, cosmetics or foodstuffs; testing, inspection or research of medical treatment and technique; research in the field of biotechnology and antibodies; providing information of testing, inspection or research of medical treatment and technique; scientific research of health care; testing, inspection or research of biology; computer software design, computer programming, or maintenance of computer software; computer hardware design and development; computer software design and development; consultancy and providing information in the field of development of pharmaceutical preparations; consultancy and providing information in the field of biomedical research |
| GS0441 | Medical services; medical services in the field of immunity, cardiology, rheumatology, oncology, pneumology, neurology; providing medical information; medical services, namely, conducting physical medical examinations in the fields of keloid scar formation, dermal burns, lymphomas, sarcomas, carcinomas, and leukemias, inflammatory disease, cardiovascular disease, atherosclerosis, rheumatoid arthritis, stroke or an acute coronary syndrome such as myocardial infarction heart attack, chronic liver disease, cerebral venous thrombosis, deep venous thrombosis or pulmonary embolism, arterial thrombosis, aneurysm, heart failure, ischemic heart diseases, angina pectoris, sudden cardiac death, hypertensive heart disease, non-coronary vessel disease, such as atherosclerosis, small vessel disease, vascular dementia, nephropathy, hypertriglyceridemia, hypercholesterolemia, hyperlipidemia, xanthomatosis, asthma, hypertension, emphysema, chronic pulmonary disease, cardiomyopathies and a cardiovascular condition associated with an interventional procedure such as restenosis following angioplasty, placement of a stent, synthetic or neutral extension grafts; medical services, namely, conducting physical medical examinations in the fields of metabolic diseases including diabetes mellitus; preparation and dispensing of medications; dietary and nutritional guidance; providing information of health care; consulting in the field of medicine, occupational therapy, and nutrition; veterinary services; beauty salons; animal sanitary services, namely, animal grooming services, animal health care, and veterinary services in the nature of euthanasia of animals; health care; consultancy and providing information in the fields of medical imaging, diagnostic properties of pharmaceuticals, and medical care related to human physiology and pathophysiology; pharmaceutical consultation; providing information relating to diagnostic, prophylactic and therapeutic properties of pharmaceuticals; physical performance monitoring in the nature of physical therapy or physiotherapy services; ergometry, namely, nutrition counseling; ergometry in the nature of health assessment, namely blood tests for the evaluation of physical fitness or response to training |
| FOREGIN REGISTRATION | |
| Foreign Registration Date | 09/16/2008 |
|---|---|
| Foreign Expiration Date | 09/16/2018 |
| Country | CH |
| Foreign Registration Number | 583036 |
| PROSECUTION HISTORY | ||||
| Date | Description | Type | Code | |
|---|---|---|---|---|
| 05/15/2013 | CORRESPONDENCE RECEIVED IN LAW OFFICE | I - Incoming Correspondence | CRFA - CORRESPONDENCE RECEIVED IN LAW OFFICE | |
| 11/16/2012 | NON-FINAL ACTION E-MAILED | F - First Action | GNRT - NON-FINAL ACTION E-MAILED | |
| 11/16/2012 | NON-FINAL ACTION WRITTEN | R - Renewal | CNRT - NON-FINAL ACTION WRITTEN | |
| 02/10/2014 | WITHDRAWN FROM PUB - OG REVIEW QUERY | Z - Deletion | PBCR | |
| 01/25/2014 | LAW OFFICE PUBLICATION REVIEW COMPLETED | O - Outgoing Correspondence | PREV - LAW OFFICE PUBLICATION REVIEW COMPLETED | |
| 01/23/2014 | APPROVED FOR PUB - PRINCIPAL REGISTER | P | CNSA - APPROVED FOR PUB - PRINCIPAL REGISTER | |
| 01/23/2014 | EXAMINER'S AMENDMENT ENTERED | I - Incoming Correspondence | XAEC - EXAMINER'S AMENDMENT ENTERED | |
| 01/23/2014 | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | O - Outgoing Correspondence | GNEN | |
| 01/23/2014 | EXAMINERS AMENDMENT E-MAILED | O - Outgoing Correspondence | GNEA - EXAMINERS AMENDMENT E-MAILED | |
| 01/23/2014 | EXAMINERS AMENDMENT -WRITTEN | R - Renewal | CNEA - EXAMINERS AMENDMENT -WRITTEN | |
| 01/06/2014 | TEAS/EMAIL CORRESPONDENCE ENTERED | I - Incoming Correspondence | TEME - TEAS/EMAIL CORRESPONDENCE ENTERED | |
| 01/06/2014 | CORRESPONDENCE RECEIVED IN LAW OFFICE | I - Incoming Correspondence | CRFA - CORRESPONDENCE RECEIVED IN LAW OFFICE | |
| 12/30/2013 | ASSIGNED TO LIE | A - Allowance for Publication | ALIE - ASSIGNED TO LIE | |
| 12/06/2013 | TEAS REQUEST FOR RECONSIDERATION RECEIVED | I - Incoming Correspondence | ERFR | |
| 12/06/2013 | EX PARTE APPEAL-INSTITUTED | T - TTAB Proceeding | EXPI - EX PARTE APPEAL-INSTITUTED | |
| 12/06/2013 | JURISDICTION RESTORED TO EXAMINING ATTORNEY | T - TTAB Proceeding | JURT | |
| 12/06/2013 | EXPARTE APPEAL RECEIVED AT TTAB | T - TTAB Proceeding | EXAF - EXPARTE APPEAL RECEIVED AT TTAB | |
| 06/06/2013 | NOTIFICATION OF FINAL REFUSAL EMAILED | O - Outgoing Correspondence | GNFN | |
| 06/06/2013 | FINAL REFUSAL E-MAILED | O - Outgoing Correspondence | GNFR - FINAL REFUSAL E-MAILED | |
| 06/06/2013 | FINAL REFUSAL WRITTEN | R - Renewal | CNFR - FINAL REFUSAL WRITTEN | |
| 05/16/2013 | TEAS/EMAIL CORRESPONDENCE ENTERED | I - Incoming Correspondence | TEME - TEAS/EMAIL CORRESPONDENCE ENTERED | |
| 05/15/2013 | TEAS RESPONSE TO OFFICE ACTION RECEIVED | I - Incoming Correspondence | TROA - TEAS RESPONSE TO OFFICE ACTION RECEIVED | |
| 11/16/2012 | NOTIFICATION OF NON-FINAL ACTION E-MAILED | O - Outgoing Correspondence | GNRN | |
| 11/15/2012 | ASSIGNED TO EXAMINER | D - Assigned to Examiner | DOCK - ASSIGNED TO EXAMINER | |
| 08/13/2012 | TEAS AMENDMENT ENTERED BEFORE ATTORNEY ASSIGNED | I - Incoming Correspondence | TAEA | |
| 08/13/2012 | TEAS VOLUNTARY AMENDMENT RECEIVED | I - Incoming Correspondence | PARI - TEAS PRELIMINARY AMENDMENT RECEIVED | |
| 07/27/2012 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM | I - Incoming Correspondence | NWOS | |
| 07/25/2012 | NEW APPLICATION ENTERED IN TRAM | I - Incoming Correspondence | NWAP - NEW APPLICATION ENTERED IN TRAM | |
Information gathered on 12/31/2009. No claim is made regarding the current trademark status. This page is not to be used as legal documentation. Always consult a licensed attorney.
Based on public records. Inadvertent errors are possible.
This web site is not associated with, endorsed by, or sponsored by and has no official or unofficial affiliation with the trademark's owners.
This web site is not associated with, endorsed by, or sponsored by and has no official or unofficial affiliation with the trademark's owners.